New immunotherapy combo targets High-Risk prostate cancer before and after surgery
NCT ID NCT06765902
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed for men with high-risk prostate cancer who are scheduled for prostate removal surgery. It planned to give a combination of three immunotherapy drugs (N-803, ETBX-071, and M-CENK) both before and after surgery to see if it could help prevent the cancer from coming back. The trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New scan could reveal hidden cancer in High-Risk prostate patients
- Promising prostate cancer combo trial pulled before starting
- New scan could revolutionize prostate cancer monitoring
- New cocktail aims to wipe out prostate cancer before surgery
- New drug cocktail aims to wipe out aggressive prostate cancer before surgery
- New cocktail aims to wipe out High-Risk prostate cancer before surgery